Quarterly report pursuant to Section 13 or 15(d)

Business combinations - Gain on bargain purchase (Details)

v3.24.3
Business combinations - Gain on bargain purchase (Details)
3 Months Ended 9 Months Ended
Jun. 01, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
May 31, 2023
$ / shares
Mar. 06, 2023
$ / shares
Business Acquisition [Line Items]          
Gain on bargain purchase     $ 22,049,000    
Remeasurement on bargain purchase   $ 106,000      
TCR2 Therapeutics          
Business Acquisition [Line Items]          
Purchase consideration $ (61,726,000)        
Net assets acquired and liabilities assumed 83,775,000        
Gain on bargain purchase $ 22,049,000   $ 22,000,000.0    
Remeasurement on bargain purchase   $ (106,000)      
Ratio for issuance of Company's ADSs for each TCR2 stock acquired         1.5117
Closing price of Company's ADS | $ / shares       $ 1.02 $ 1.32